The Gastroesophageal Junction Adenocarcinoma Therapeutics market was valued at USD 5.75 Billion in 2024 and is expected to reach USD 20.99 Billion by 2032, growing at a CAGR of 17.56% (2025-2032). Get insights on trends, segmentation, and key players with Data Bridge Market Research Reports.